185490 Stock Chart & Stats
₩1502.00
-₩5.00(-0.33%)
―
--
Day’s Range― - ―
52-Week Range₩1,182.00 - ₩2,952.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)169.22K
Market Cap
₩64.92B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,229,782
10 Day Avg. Volume132,882
30 Day Avg. Volume169,218
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6,158,085.83
Revenue Forecast (FY)₩6.17T
185490 FAQ
What was EyeGene, Inc.’s price range in the past 12 months?
EyeGene, Inc. lowest stock price was ₩1182.00 and its highest was ₩2952.71 in the past 12 months.
What is EyeGene, Inc.’s market cap?
EyeGene, Inc.’s market cap is ₩64.92B.
When is EyeGene, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were EyeGene, Inc.’s earnings last quarter?
Currently, no data Available
Is EyeGene, Inc. overvalued?
According to Wall Street analysts EyeGene, Inc.’s price is currently Undervalued.
Does EyeGene, Inc. pay dividends?
EyeGene, Inc. does not currently pay dividends.
What is EyeGene, Inc.’s EPS estimate?
EyeGene, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EyeGene, Inc. have?
EyeGene, Inc. has 43,229,782 shares outstanding.
What happened to EyeGene, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of EyeGene, Inc.?
Currently, no hedge funds are holding shares in KR:185490
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
iNtRON Biotechnology, Inc.
―
Genesem, Inc.
―
CytoGen, Inc.
―
PanGen Biotech, Inc.
―
KoBioLabs, Inc.
―